GE HealthCare (Nasdaq: GEHC) today announced the launch of its CleaRecon DL technology for enhancing CBCT imaging.
The company recently received FDA 510(k) clearance and CE mark for the technology powered by a deep learning algorithm. It plans to roll out the AI-driven solution, designed to improve the quality of cone-beam computed tomography (CBCT) images, in the U.S. and Europe for use on the Allia platform.
CleaRecon DL brings AI-based 3D reconstruction to the interventional suite. It utilizes AI-based reconstruction to improve image quality by removing streaks without introducing additional artifacts. The company says it also designed the solution to improve CBCT analysis through clear images. According to GE HealthCare, it offers benefits in liver, prostate, neuro and endovascular aortic repair procedures.
The company says CleaRecon DL harnesses deep learning to provide clearer and more accurate imaging. It enables healthcare professionals to make better-informed decisions and improve their patient care. GE HealthCare hopes to advance its vision of accelerating CBCT adoption in daily practice.
“The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT. By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence,” said Arnaud Marie, GM, Interventional Solutions at GE HealthCare. “This solution builds on our portfolio of tools aimed at improving the user experience and workflow efficiency, enabling clinicians to deliver more accurate and effective interventions for enhanced patient outcomes.”
